Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 2/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267057 | 0.91 | MAPKAPK2 (0.37) | MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL4255905 | 0.91 | MAPKAPK2 (0.40) | MAPKAPK2SIGMAR1IRAK1 | |
| SCHEMBL4255920 | 0.91 | CSNK1A1 (0.45) | MAPKAPK2CSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL4258589 | 0.88 | MAPKAPK2 (0.57) | MAPKAPK2 | |
| SCHEMBL4259022 | 0.83 | TMEM97 (0.39) | MAPKAPK2SIGMAR1 | |
| SCHEMBL4150539 | 0.83 | CDK2 (0.51) | — | |
| SCHEMBL4260865 | 0.82 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL13852037 | 0.82 | SIGMAR1 (0.33) | MAPKAPK2SIGMAR1IRAK1 | |
| SCHEMBL4160344 | 0.82 | KDM4E (0.36) | MAPKAPK2SIGMAR1 | |
| SCHEMBL4442281 | 0.78 | PARP10 (0.46) | MAPKAPK2CSNK1A1CSNK1DGSK3BCSNK1G2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885HTR2C 1043/4885ADK 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.